1. Home
  2. ATAI vs HPP Comparison

ATAI vs HPP Comparison

Compare ATAI & HPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATAI
  • HPP
  • Stock Information
  • Founded
  • ATAI 2018
  • HPP 1997
  • Country
  • ATAI Netherlands
  • HPP United States
  • Employees
  • ATAI N/A
  • HPP N/A
  • Industry
  • ATAI Biotechnology: Pharmaceutical Preparations
  • HPP Real Estate
  • Sector
  • ATAI Health Care
  • HPP Finance
  • Exchange
  • ATAI Nasdaq
  • HPP Nasdaq
  • Market Cap
  • ATAI 1.1B
  • HPP 940.3M
  • IPO Year
  • ATAI 2021
  • HPP 2010
  • Fundamental
  • Price
  • ATAI $5.88
  • HPP $2.46
  • Analyst Decision
  • ATAI Strong Buy
  • HPP Hold
  • Analyst Count
  • ATAI 5
  • HPP 11
  • Target Price
  • ATAI $14.00
  • HPP $3.04
  • AVG Volume (30 Days)
  • ATAI 7.1M
  • HPP 3.9M
  • Earning Date
  • ATAI 11-14-2025
  • HPP 11-05-2025
  • Dividend Yield
  • ATAI N/A
  • HPP N/A
  • EPS Growth
  • ATAI N/A
  • HPP N/A
  • EPS
  • ATAI N/A
  • HPP N/A
  • Revenue
  • ATAI $2,309,000.00
  • HPP $792,977,000.00
  • Revenue This Year
  • ATAI $736.04
  • HPP N/A
  • Revenue Next Year
  • ATAI N/A
  • HPP $6.87
  • P/E Ratio
  • ATAI N/A
  • HPP N/A
  • Revenue Growth
  • ATAI 510.85
  • HPP N/A
  • 52 Week Low
  • ATAI $1.04
  • HPP $1.78
  • 52 Week High
  • ATAI $6.75
  • HPP $4.67
  • Technical
  • Relative Strength Index (RSI)
  • ATAI 52.01
  • HPP 39.32
  • Support Level
  • ATAI $5.50
  • HPP $2.31
  • Resistance Level
  • ATAI $6.23
  • HPP $2.52
  • Average True Range (ATR)
  • ATAI 0.46
  • HPP 0.12
  • MACD
  • ATAI -0.06
  • HPP -0.01
  • Stochastic Oscillator
  • ATAI 26.71
  • HPP 27.51

About ATAI ATAI Life Sciences N.V.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

About HPP Hudson Pacific Properties Inc.

Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.

Share on Social Networks: